Oyster Point Pharma Stock News

Zacks Investment Research upgraded shares of Oyster Point Pharma (NASDAQ:OYST) from a sell rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Oyster Point Pharma Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of pharmaceutical therapies to treat []

PRINCETON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of

Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q3 2021 Results - Earnings Call Transcript

PRINCETON, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of

The FDA approval of nasal spray Tirvaya didn't include data needed for the company to receive the second tranche in its credit facility.

The FDA has approved Oyster Point Pharma Inc (NASDAQ: OYST) Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for signs and symptoms of dry eye disease.  Tyrvaya Nasal Spray is the first and only

The stock price of Oyster Point Pharma Inc (NASDAQ: OYST) increased by over 14% pre-market today. This is why it happened.

PRINCETON, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of

Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q2 2021 Results - Earnings Call Transcript

Oyster Point Pharma Inc (NASDAQ: OYST) has announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize OC-01 (varenicline) and OC-02 (simp

PRINCETON, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma” or “the Company”) a clinical-stage biopharmaceutical company focused on the

Conference Call and Webcast Scheduled for August 5, 2021, 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for August 5, 2021, 4:30 p.m. Eastern Time

PRINCETON, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of

Donald Santel joins as Chairman of the Board of Directors Donald Santel joins as Chairman of the Board of Directors

PRINCETON, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced preclinical data in non-human primates and in vitro models evaluating OC-01 (varenicline) n